tbuckley/cabot-search huggingface dataset:
THE VACCINATED WORLD
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Percutaneous intramyocardial delivery is an efficient modality for local myocardial treatment Mehrdad Rezaee, Alan C. Yeung, Peter Altman, Takeshi Suzuki, Dieter Lubbe, Robert S. Schwartz, Simon H. Stertzer, John D. Altman. Stanford University Medical Center, Stanford, CA, Mayo Clinic Foundation, Rochester, MN
Journal: Journal of the American College of Cardiology (2001)
Letter to the Editor
Authors: Giovanni A. Fava, G. Ba, E. Fava, I. Carta, M. Clerici, S. Albonetti, R. Papa, G. Penati, G. Invernizzi, James D.A. Parker, Graeme J. Taylor, Michael Bagby, Robert Kellner, Juan Hernandez, Dorothy Pathak, Töres Theorell, Jenifer Wilson-Barnett, L.G. Sobrinho, J.M. Almeida-Costa
Journal: Psychotherapy and Psychosomatics (1992)
Central Nervous System Effects Following Ingestion of L-Tryptophan by Normal Subjects
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CAUSE OF CRIMINALITY AND DEFECTIVENESS.
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038).
Authors: Sherise C. Rogers, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Z. Hugh Fan, Carmen Joseph Allegra, Jose Trevino, Ahmad El-Far, Anita Ahmed Turk, Karen Bullock Russell, David L. DeRemer, Thomas J. George
Journal: Journal of Clinical Oncology (2021)

TPS4170 Background: Neoadjuvant treatment for potentially curable pancreatic cancer (PDAC) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demonstrated feasibility and effectiveness of the FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin and irinotecan) regimen in the perioperative setting. However, FOLFIRINOX often requires dose modifications, delays and growth factor support due to excessive toxicity which can complicate care delivery when given neoadjuvantly. Liposomal irinotecan injection (Nal-IRI) is FDA approved with a well-tolerated safety profile in relapsed, refractory metastatic PDAC. The current study aims to substitute Nal-IRI for traditional irinotecan in the standard FOLFIRINOX regimen (NALIRIFOX) and to demonstrate safe and effective neoadjuvant delivery. Methods: This phase 2, open-label, multicenter single-arm study focuses on patients (pts) with operable PDAC without metastatic disease. Other key eligibility criteria include age ≥18 years, resectability confirmed by multiD GI tumor board (resectable vs. borderline), adequate cardiac, renal, hepatic function and ECOG performance status of 0 to 1. Pts receive NALIRIFOX regimen as per the table every 2 weeks for four months followed by disease reassessment. Pts who remain surgical candidates will undergo surgical resection within 4 to 8 weeks following last dose of therapy. The primary endpoint is to assess safety and feasibility of regimen in perioperative setting. Secondary endpoints include R0 resection rate, clinical, biochemical and radiological response rate and patient-reported quality of life during treatment as measured by the NCI validated FACT-G scale. Enrollment continues to a maximum of 28 evaluable pts to demonstrate a reduction in historical 30 day postoperative complication rate. NCT03483038. NALIRIFOX regimen components given intravenously (IV) every 14 days. Clinical trial information: NCT03483038. [Table: see text]
Citation Accuracy vs Citation Integrity
Authors: Ryan Howard, Michael Englesbe
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Systematic analysis of gene expression alteration of BIRC5/survivn in gastric cancer.
Authors: Jianzheng Wang, Qingli Li, Huifang Lv, Xiaobing Chen, Shuiping Tu
Journal: Journal of Clinical Oncology (2022)

353 Background: BIRC5/survivin gene is a member of the inhibitor of apoptosis (IAP) gene family, which encode negative regulatory proteins that prevent apoptotic cell death. Abnormal BIRC5/survivin expression is associated with carcinogenesis. Methods: We used sequencing data from The Cancer Genome Atlas database，Oncomine database and GTEx database, analyzed BIRC5/survivin expression and gene regulation networks in gastric carcinoma (STAD).Kaplan-Meier plotter database was used to assess the BIRC5/survivin prognostic potential. ULACAN was used to further analyze the relationship between the expression of BIRC5/survivin and the clinical stage of gastric cancer, and the methylation data of the promoter region of BIRC5/survivin. LinkedOmics was used to identify differential gene expression with BIRC5/survivin and to analyze Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways. Gene enrichment analysis examined target networks of kinases, miRNAs and transcription factors. We investigated the correlation of BIRC5/survivin expression in gastric cancer with immune infiltration levels from TIMER database and TISID database. Results: We found that BIRC5/survivin is overexpressed in gastric cancer. The patient with high expression of this gene is associated with poor prognosis. The expression of BIRC5/survivin is positive with ERBB2 expression,TMB,MSI,MSH2,MSH6,PMS2.BIRC5/surviving expression is significantly positively correlated to tumor purity and has significant negative correlation with the immune cell infiltration level of B cells,CD8+T cells,CD4+T cells, Macrophage cells, Neutrophil cells and Dendritic cells. BIRC5/survivin expression is significantly positively correlated CD274，LAG3 and PDCD1. Our results show a detailed landscape map of BIRC5/survivin gene mutation in STAD. Our results showed the associations between BIRC5/survivin expression and six immune subtypes: C1 (wound healing); C2 (IFN-gamma dominant);C3 (inflammatory); C4 (lymphocyte depleted); C6 (TGF-b dominant) in STAD. Conclusions: Our results demonstrate that data mining efficiently reveals information about BIRC5/survivin expression and potential regulatory networks in gastric cancer, laying a foundation for further study of the role of BIRC5/survivin in carcinogenesis and tumor immunotherapy.
Abstract 482: A Novel Small Molecule Inhibitor of Acetyltransferase p300 Ameliorates Hypertension-Induced Cardiac and Renal Fibrosis
Authors: Rahul Rai, Suresh K Verma, David Kim, Veronica Ramirez, Chengjin Li, Susmita Sahoo, Gangjian Qin, Raj Kishore, Lisa D Wilsbacher, Douglas E Vaughan, Susan E Quaggin, Asish K Ghosh
Journal: Circulation Research (2017)

Rationale: Fibrosis is a common pathophysiological manifestation of chronically injured or stress-affected organs. Additionally, cardiac and renal fibrosis remain leading causes of global morbidity and mortality. Meanwhile, no effective therapy is available to halt the onset and progression of cardiac and renal fibrogenesis. We have previously demonstrated that p300 with intrinsic factor acetyltransferase (FATp300) activity is an essential epigenetic regulator of profibrogenic signal-induced matrix protein synthesis. Objective: Here, we attempted to delineate the therapeutic efficacy of a small molecule inhibitor of FATp300, L002, in blocking i) TGF-b-induced profibrogenic processes in cardiac and renal cells in vitro, and ii) Angiotensin II-induced cardiac and renal fibrogenesis in mice. Methods and Results: Analysis of cardiac and renal cells demonstrates that L002 inhibits specific histone acetylation and blunts TGF-b induced profibrogenic processes, including cellular proliferation, migration, myofibroblast differentiation and extracellular matrix protein synthesis. The mRNA analysis further indicates that matrix protein, collagen, and myofibroblast marker, a-SMA are inhibited at the transcriptional level. L002 also prevents TGF-b-induced FATp300 upregulation suggesting that TGF-b-induced FATp300 expression is partly self-regulated. However, TGF-b-induced Smad activation is unaltered in the presence of L002, demonstrating its target specificity. Further, mice infused with Angiotensin II show increased blood pressure, cardiac hypertrophy and increased heart weight. Conversely, co-administration of L002 reduces Angiotensin II-induced cardiac hypertrophy and left ventricular wall thickness. Most importantly, L002 administration ameliorates Angiotensin II-induced cardiac and renal fibrosis in mice. Conclusions: Taken together this study demonstrates that specific pharmacological inhibition of elevated factor acetyltransferase activity of p300, a major epigenetic regulator, is an ideal approach to control hypertension- or other stress-induced cardiac and renal fibrogenesis as seen in a wide variety of cardiovascular and renal diseases.
Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: One institutional experience in Taiwan since 2016.
Authors: Jo-Pai Chen, Wei-Chen Lu, Hsu Wu, Tsui-Mai Kao, Keng-Man Chiang, Hsing-wu Chen, Sung-Hsin Kuo
Journal: Journal of Clinical Oncology (2022)

328 Background: ESCC is a health burden in Taiwan due to smoking and drinking habits. In R/M setting, the prognosis is worse. In 2021, KN590 study(pembrolizumab with chemotherapy in CPS≥10%), CM648 study(nivolumab with chemotherapy or nivolumab with ipilimumab in TPS≥1%), and ESCORt-1st study(camrelizumab with chemotherapy in TPS≥1%) have all been shown to get survival benefits compared with chemotherapy alone in front-line setting. Further immunotherapy combinations with targeted therapies and subsequent therapy options after anti-PD1 failure deserve more investigation. Methods: From early 2016 to late 2021, 26 advanced ESCC patients had ever received immunotherapy-containing regimens in Yun-lin Branch of National Taiwan University Hospital. We have reviewed basic characters, ICIs regimens, and treatment response of these patients. Results: 3 patients under progression during front-line KN590 got PR by subsequent afatinib(2) or lenvatinib(1) use. So, the overall response rate of advanced ESCC to immunotherapy-containing regimens was 59%(17/29) and disease control rate was 72%(21/29). Conclusions: Afatinib has multiple immuno-modulatory effects. AP or NA is an effective regimen in Taiwan, where double cancers, like HNSCC and ESCC, are popular due to smoking, drinking, and bêtel-nuts chewing. Following KN590 good efficacy was also seen in our institution and afatinib with anti-PD1 could be introduced in CT-unfit patients. In unresectable and/or oligometastatic ESCC, induction triple therapy may lead to conversion chemoradiation, even to final surgery. EGFR or VEGFR TKI with immunotherapy might also be a subsequent recue regimen after front-line anti-PD1 failure.[Table: see text]
Stents for the treatment of in-stent restenosis: Long-term outcome David R. Holmes, Jr., Peter B. Berger, Charanjit S. Rihal, Kirk N. Garratt, Malcolm R. Bell, Verg Matthew, John F. Bresnahan, Greg W. Barsness, Diane Grill. Mayo Medical Center, Rochester, MN
Journal: Journal of the American College of Cardiology (2001)
Abstract PS1-32: A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients
Authors: Amit Goyal, Shama Puri, Andrea Marshall, Kalliope Valassiadou, Moin Hoosein, Amtul R Carmichael, Gabriella Erdelyi, Nisha Sharma, Janet Dunn, Joanne York
Journal: Cancer Research (2021)

Abstract Background: The primary aim of this prospective, multicentre feasibility study was to determine whether the biopsied axillary node in patients with breast cancer can be marked using black carbon dye and successfully identified at the time of surgery. Methods: We included patients undergoing needle biopsy of the axillary lymph gland. The biopsied node was tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or at a separate visit with black carbon dye (Spot™ or Black Eye™). Participants underwent primary surgery or neoadjuvant chemotherapy and axillary surgery (SNB or ALND) as per routine care. Results: 110 patients were included. Median age of the women was 59 (range 31 to 88) years. 48 of 110 (44%) underwent SNB and 62 (56%) ALND. The median volume of dye injected was 2.0 ml (range 0.2-4.2).Tattooed node was identified in 90 of 110 (82%) patients. The identification rate was higher (86%) in the primary surgery group compared with NACT (64%). Of those undergoing NACT, the identification rate was better in the patients undergoing SNB (3 of 4, 75%) compared with ALND (11 of 18, 61%). The tattooed node was the sentinel node in 78% (28 of 36) patients in the primary surgery group and 100% (3 of 3) in the NACT group. For surgeons who had performed ≥5 operations, there was no learning curve. The identification rate did not vary with body mass index or volume of dye injected. There was no correlation between volume of dye and number of tattooed nodes removed. Conclusion: It is feasible to mark the axillary node with carbon dye and identify it intraoperatively. Modifications of the technique, such as injecting the dye in the cortex alone, restricting the volume to 0.2 to 0.4 ml and combining with clip, will improve the technical ability to identify the marked node. Citation Format: Amit Goyal, Shama Puri, Andrea Marshall, Kalliope Valassiadou, Moin Hoosein, Amtul R Carmichael, Gabriella Erdelyi, Nisha Sharma, Janet Dunn, Joanne York. A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS1-32.
Extracellular vesicles derived from neural EGFL-Like 1-modified mesenchymal stem cells improve acellular bone regeneration via the miR-25-5p-SMAD2 signaling axis
Authors: Yanhua Lan, Huizhi Xie, Qianrui Jin, Xiaomin Zhao, Yang Shi, Yanyan Zhou, Zihe Hu, Yi Ye, Xiaoyuan Huang, Yingjia Sun, Zhuo Chen, Zhijian Xie
Journal: Bioactive Materials (2022)

Stem cell based transplants effectively regenerate tissues; however, limitations such as immune rejection and teratoma formation prevent their application. Extracellular vesicles (EVs)-mediated acellular tissue regeneration is a promising alternative to stem cell based transplants. Although neural EGFL-like 1 (Nell1) is known to contribute to the osteogenic differentiation of bone marrow stem cells (BMSCs), it remains unknown whether EVs are involved in this process. Here, we present that EVs derived from Nell1-modified BMSCs (Nell1/EVs) have a stronger ability to promote BMSC osteogenesis owing to miR-25-5p downregulation. MiR-25-5p inhibits osteogenesis by targeting Smad2 and suppressing the SMAD and extracellular signal-related kinase 1 and 2 (ERK1/2) pathway activation. In addition, we demonstrate that the 3D-Nell1/EV-hydrogel system is beneficial for bone regeneration in vivo, probably stemming from a slow, continuous release and high concentration of EVs in the bone defect area. Thus, our results have shown the potential of Nell1/EVs as a novel acellular bone regeneration strategy. Mechanistically, the identification of miR-25-5p-SMAD2 signaling axis expands the knowledge of Nell1/EVs induced osteogenesis.
Books Received
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Should physicians screen for mild thyroid failure?
Authors: H. G. Welch
Journal: JAMA (1996)

<h3>In Reply.</h3> —Drs Welch and Birkmeyer highlight 2 important points in our analysis of screening for mild thyroid failure. The first point is that the utility (or health-related quality of life) for patients with mild thyroid failure may be too low at 0.90. It is important to recognize that only 28% of patients with mild thyroid failure (high TSH and normal free thyroxine levels) were assigned a utility of 0.90 and considered to have some reversible symptoms of thyroid hormone deficiency. The remaining 72% of patients were assumed to have maximum quality of life. Thus, the average utility for patients in the state of mild thyroid failure is 0.97, not 0.90. However, even this conservative estimate does not negate the fact that the utility of mild thyroid failure with symptoms is an important issue in screening. In sensitivity analyses, this variable was second only to the cost of the TSH assay in